Pancreatic Ductal Adenocarcinoma
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Pancreatic Ductal Adenocarcinoma

What is the definition of Pancreatic Ductal Adenocarcinoma?
Pancreatic ductal adenocarcinoma is an aggressive cancer that occurs in the linings of the tubes of the pancreas that carry enzymes to the intestines that assist with digestion.
What are the symptoms of Pancreatic Ductal Adenocarcinoma?
Early pancreatic ductal adenocarcinoma may not have any symptoms. Symptoms of pancreatic ductal adenocarcinoma may include yellowing of the skin and whites of the eyes, fatigue, dark urine, light-colored or greasy stools, itchy skin, abdominal or back pain, weight loss, nausea and vomiting, gallbladder or liver enlargement, blood clots, and diabetes.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Pancreatic Ductal Adenocarcinoma?
Treatment for pancreatic ductal adenocarcinoma includes surgery, radiation therapy, and chemotherapy.
Who are the top Pancreatic Ductal Adenocarcinoma Local Doctors?
Elite in Pancreatic Ductal Adenocarcinoma
General Surgery | Oncology
Elite in Pancreatic Ductal Adenocarcinoma
General Surgery | Oncology
Referral may be required

Jefferson Surgery - Honickman Center

1101 Chestnut Street, Floor 8, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Charles Yeo is an Oncologist and a General Surgeon practicing medicine in Philadelphia, Pennsylvania. Dr. Yeo is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Yeo is board certified in Surgery. Dr. Yeo is currently accepting new patients.

Elite in Pancreatic Ductal Adenocarcinoma
Surgical Oncology
Elite in Pancreatic Ductal Adenocarcinoma
Surgical Oncology
Referral may be required

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
Experience:
18+ years
Languages Spoken:
English
Offers Telehealth

Richard Burkhart, M.D., is an Associate Professor of Surgery at The Johns Hopkins Hospital with a focus on complex minimally-invasive surgery and research for cancers of the pancreas, liver and bile ducts. Dr. Burkhart received his medical degree from Boston University and completed his surgical residency and research fellowships at the Thomas Jefferson University Hospital in Philadelphia and the Cold Spring Harbor Laboratories. He is a member of several professional organizations, including the American Association of Cancer Research, the American College of Surgeons, the Society of Surgery for the Alimentary Tract, the Pancreas Club, and the Society of Surgical Oncology. Outside the operating room, Dr. Burkhart heads a multidisciplinary laboratory team dedicated to bringing next-generation precision medicine approaches into the routine clinical care of patients that we serve. He has a particular research interest in using personalized models of pancreas cancer, made from tumor during and immediately after surgical resection, to select the best chemotherapy for each patient to support long-term survival and improve rates of disease cure. The laboratory team, funded in part by the National Institutes of Health, the National Cancer Institute, the Lustgarten Foundation and Stand Up to Cancer, is also thankful to the many patients who have supported the work through philanthropic gift. Dr. Burkhart is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Burkhart is board certified in American Board Of Surgery.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Pancreatic Ductal Adenocarcinoma
Elite in Pancreatic Ductal Adenocarcinoma
Referral may be required

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
Languages Spoken:
English, Spanish
Accepting New Patients
Offers Telehealth

I enjoy traveling, dancing and food. Dr. Shroff is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Shroff is currently accepting new patients.

What are the latest Pancreatic Ductal Adenocarcinoma Clinical Trials?
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Summary: Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these ducts. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan wh...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Summary: This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the t...